摘要
目的探讨局部晚期宫颈鳞癌(cervical squamous cell carcinoma,CSCC)患者外周血和癌组织中T细胞上表达B、T细胞弱化因子(B and T lymphocyte attenuator,BTLA)的差异,初步评价其与近期疗效的关系。方法收集新疆医科大学附属肿瘤医院2017年1-10月收治的45例CSCC患者,采用流式细胞术检测患者外周血和癌组织中T细胞上BTLA的表达量,并结合临床资料对比分析。结果局部晚期CSCC外周血中CD4+T细胞上BTLA的表达量(60.60%)高于CSCC组织(0.57%),其差异有统计学意义(P<0.001);CSCCBTLA外周血CD8+T细胞上的表达量(32.20%)高于CSCC组织(1.04%),其差异有统计学意义(P<0.001);结节型CSCC外周血CD8+T细胞BTLA的表达量(33.40%)高于菜花型(25.60%);低分化CSCC患者癌组织CD8+T细胞上BTLA的表达量(2.99%)高于中分化(0.72%),差异君有统计学意义(P=0.011,P=0.034);BTLA在有、无恶性肿瘤家族史的CSCC患者癌组织CD4+、CD8+T细胞上的分别为表达量(7.04%、6.96%、0.54%、0.99%),差异均有统计学意义(P<0.05)。结论BTLA在局部晚期CSCC患者癌组织T细胞上的表达低于外周血,提示应用抗BTLA治疗CSCC可能会导致机体产生较严重的全身免疫相关不良反应,推测BTLA可能不是CSCC免疫治疗的理想靶点。
Objective To explore the difference of B and T lymphocyte attenuator(BTLA)expressed in peripheral blood and in locally advanced cervical squamous cell carcinoma(CSCC)patients,and to preliminarily evaluate the relationship between the short-term efficacy and the lymphocyte.Methods A total of 45 patients with CSCC admitted to the Affiliated Tumor Hospital of Xinjiang Medical University from January 2017 to October 2017 were collected.Flow cytometry was used to detect the expression of BTLA on T cells in peripheral blood and cancer tissues of patients,and the clinical data were compared and analyzed.Results The expression level of BTLA on CD4+T cells in the peripheral blood of patients with locally advanced CSCC(60.60%)was significantly higher than that of cancer tissues(0.57%),and the difference was statistically significant(P<0.001).The expression level of BTLA in CD8+T cells in the peripheral blood(32.20%)was significantly higher than that in the cancer tissues(1.04%),and the difference was statistically significant(P<0.001).The expression level of BTLA on CD8+T cells in the peripheral blood of nodular CSCC patients(33.40%)was higher than that of cauliflower-type patients(25.60%),and the difference was statistically significant(P=0.011).The expression level of BTLA on CD8+T cells in the cancer tissues of patients with poorly differentiated CSCC(2.99%)was higher than that of patients with moderately differentiated CSCC(0.72%),and the difference was statistically significant(P=0.034).The expression level of BTLA onCD4+andCD8+T cells in the cancer tissues of the CSCC patients with a family history of malignant tumor(7.04%,6.96%)was higher than that of patients without a family history of malignant tumor(0.54%,0.99%),and the difference was statistically significant(P<0.05).Conclusion The expression of BTLA on T cells in the peripheral blood of patients with locally advanced CSCC was significantly higher than that in the cancer tissues,suggesting that the application of anti-BTLA in the treatment of CSCC may lead to s
作者
张典刚
王晓青
王若峥
ZHANG Diangang;WANG Xiaoqing;WANG Ruozheng(Departments of Radiotherapy Center, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, China;Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi 830011, China;Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi 830011, China;Xinjiang Yili Friendship Hospital, YiLi 835000, China)
出处
《新疆医科大学学报》
CAS
2020年第9期1143-1149,共7页
Journal of Xinjiang Medical University
基金
国家自然科学基金(U1603282)
中国医学科学院院外重点实验室建设项目(2018PT31050)。
关键词
BTLA
宫颈鳞癌
T细胞
免疫治疗
B and T lymphocyte attenuator(BTLA)
cervical squamous cell carcinoma(CSCC)
T cells
immunotherapy
